I Cortese - JoVE Visualize

Showing results (11-20 of 21) with videos related to

Pageof 3

Sort By:

The Journal of Clinical Investigation|October 17, 2001

CD4+CD28- costimulation-independent T cells in multiple sclerosisS Markovic-Plese, I Cortese, K P Wandinger, et al.

Proceedings of the National Academy of Sciences of the United States of America|October 1, 1996

Identification of peptides specific for cerebrospinal fluid antibodies in multiple sclerosis by using phage librariesI Cortese, R Tafi, L M Grimaldi, et al.

Multiple Sclerosis (Houndmills, Basingstoke, England)|April 9, 1998

Identification of peptides binding to IgG in the CSF of multiple sclerosis patientsI Cortese, S Capone, R Tafi, et al.

Multiple Sclerosis (Houndmills, Basingstoke, England)|October 8, 1998

CSF-enriched antibodies do not share specificities among MS patientsI Cortese, S Capone, S Luchetti, et al.

Neurology|January 19, 2011

Evidence-based guideline update: Plasmapheresis in neurologic disorders [RETIRED]: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of NeurologyI Cortese, V Chaudhry, Y T So, et al.

Pharmacological Research|September 10, 1999

Effects of early postnatal exposure to low concentrations of carbon monoxide on cognitive functions in ratsM Tattoli, M R Carratù, T Cassano, et al.

Nature Immunology|September 19, 2001

Dendritic cells signal T cells in the absence of exogenous antigenT Kondo, I Cortese, S Markovic-Plese, et al.

Current Opinion in Biotechnology|December 1, 1996

Selection of biologically active peptides by phage display of random peptide librariesR Cortese, P Monaci, A Luzzago, et al.

International Immunology|March 4, 2000

Minimal peptide length requirements for CD4(+) T cell clones--implications for molecular mimicry and T cell survivalB Hemmer, T Kondo, B Gran, et al.

Nature Medicine|October 4, 2000

Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligandB Bielekova, B Goodwin, N Richert, et al.

Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:

Pageof 3

The Journal of Clinical Investigation|October 17, 2001

CD4+CD28- costimulation-independent T cells in multiple sclerosisS Markovic-Plese, I Cortese, K P Wandinger, et al.

Proceedings of the National Academy of Sciences of the United States of America|October 1, 1996

Identification of peptides specific for cerebrospinal fluid antibodies in multiple sclerosis by using phage librariesI Cortese, R Tafi, L M Grimaldi, et al.

Multiple Sclerosis (Houndmills, Basingstoke, England)|April 9, 1998

Identification of peptides binding to IgG in the CSF of multiple sclerosis patientsI Cortese, S Capone, R Tafi, et al.

Multiple Sclerosis (Houndmills, Basingstoke, England)|October 8, 1998

CSF-enriched antibodies do not share specificities among MS patientsI Cortese, S Capone, S Luchetti, et al.

Neurology|January 19, 2011

Evidence-based guideline update: Plasmapheresis in neurologic disorders [RETIRED]: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of NeurologyI Cortese, V Chaudhry, Y T So, et al.

Pharmacological Research|September 10, 1999

Effects of early postnatal exposure to low concentrations of carbon monoxide on cognitive functions in ratsM Tattoli, M R Carratù, T Cassano, et al.

Nature Immunology|September 19, 2001

Dendritic cells signal T cells in the absence of exogenous antigenT Kondo, I Cortese, S Markovic-Plese, et al.

Current Opinion in Biotechnology|December 1, 1996

Selection of biologically active peptides by phage display of random peptide librariesR Cortese, P Monaci, A Luzzago, et al.

International Immunology|March 4, 2000

Minimal peptide length requirements for CD4(+) T cell clones--implications for molecular mimicry and T cell survivalB Hemmer, T Kondo, B Gran, et al.

Nature Medicine|October 4, 2000

Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligandB Bielekova, B Goodwin, N Richert, et al.

Pageof 3